Joint project teams from the University of Melbourne and Sanofi Pasteur will collaborate on the development and execution of specific programs yet to be identified. The global healthcare leader will provide support to the researchers at the University of Melbourne in developing the relevant technologies and will have the first right-of-refusal to acquire exclusive, worldwide licenses to develop and commercialise the technology.
University of Melbourne Deputy Vice-Chancellor (Research) Professor James McCluskey welcomed the strengthening of this strategic alliance.
“The University of Melbourne is excited to continue this strong alliance with Sanofi Pasteur to work towards developing the next generation of vaccines to protect the population against infectious diseases,” he said.
Sanofi Pasteur has partnered with the University on other projects, including developing an investigative vaccine to treat gingivitis and a new adjuvant – a substance added to a vaccine to boost the immune response.
Based in France, Sanofi Pasteur is the vaccine division of Sanofi (EURONEXT: SAN and NYSE: SNY) producing more than 1 billion doses of vaccines yearly to immunise more than 500 million people in the world.
The alliance was facilitated by UoM Commercial Limited, the University’s Commercial Engagement Services company.
General media enquiries:
The Media Office is staffed from
8am – 5pm Monday to Friday.
For urgent after hours media queries +61 (0)432 754 232